Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Drug development

Topic: Brain proteins, microglia and lab models

Plain-language summary

GLP-1RA use was associated with lower risk of dementia (HR 0.80, 95% CI 0.71–0.91) and Alzheimer’s disease (HR 0.76, 95% CI 0.59–0.98) compared to DPP4is. Other outcomes showed no significant differences. GLP-1RAs may reduce dementia and Alzheimer’s disease risk in advanced CKD, supporting potential neuroprotective effects beyond glycemic control. Funding: Government Support – Non-U.S.Neurodegenerative Outcomes Comparison from GLP-1RAs and DPP4is - Clinical Outcomes GLP-1RAs (n = 12,351) DDP4is (n = 12,351) GLP-1RAs vs. DDP4is Dementia 455 (3.7) 562 (4.6) 0.80 (0.71–0.91) (p=0.001) Alzheimer 109 (0.9) 142 (1.1) 0.76 (0.59–0.98) (p=0.033) Vascular dementia 173 (1.4) 182 (1.5) 0.95 (0.77–1.16) (p=0.591) Frontotemporal dementia 10 (0.1) 14 (0.1) 0.64 (0.28–1.48) (p=0.294) Dementia with Lewy bodies 11 (0.1) 15 (0.1) 0.74 (0.34–1.61) (p=0.443) Parkinson 178 (1.4) 177 (1.4) 1.00 (0.81–1.23) (p=0.992) Extrapyramidal and movement disorders 1,057 (8.6) 994 (8.0) 1.06 (0.97–1.16) (p=0.178)

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 12,351 participants. In this real-world study of people with diabetes and advanced chronic kidney disease, those taking GLP-1 receptor agonists had a lower risk of dementia and Alzheimer's disease diagnoses than those taking DPP4 inhibitors. Reported effect size: HR 0.80; HR 0.76.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Lee, W.-T. (2025). GLP-1 Receptor Agonists Reduce Dementia and Alzheimer Disease Risk in Patients with Diabetes and Advanced CKD: Real-World Evidence from TriNetX. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2025rdy8v05v

Vancouver

Lee W.-T. GLP-1 Receptor Agonists Reduce Dementia and Alzheimer Disease Risk in Patients with Diabetes and Advanced CKD: Real-World Evidence from TriNetX. Journal of the American Society of Nephrology. 2025. doi:10.1681/asn.2025rdy8v05v.

BibTeX

@article{lee2025-01baa622,
  author  = {Lee, Wen-Teng},
  title   = {{GLP-1 Receptor Agonists Reduce Dementia and Alzheimer Disease Risk in Patients with Diabetes and Advanced CKD: Real-World Evidence from TriNetX}},
  journal = {Journal of the American Society of Nephrology},
  year    = {2025},
  doi     = {10.1681/asn.2025rdy8v05v},
  url     = {https://doi.org/10.1681/asn.2025rdy8v05v}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

In this real-world study of people with diabetes and advanced chronic kidney disease, those taking GLP-1 receptor agonists had a lower risk of dementia and Alzheimer's disease diagnoses than those taking DPP4 inhibitors. No significant differences were found for other conditions such as vascular dementia or Parkinson's disease.

Study details

How this study scored 47/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 4 of 4; Effect reported 3 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record left out, no data; Institution's track record 0 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 1 of 2; Free to read 0 of 2. 45 of the 96 points it could be judged on, which is 47 of 100. Total 47 of 100.45 of the 96 points we could judge = 47 of 100

Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 45 of the 96 points we could judge it on, which is 47 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of the American Society of Nephrology)
Journal's citation record 3 / 4 Journal of the American Society of Nephrology: journal h-index 370 (OpenAlex, 2026-10-29)
Study design 7 / 12 A cohort study following people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 4 / 4 12,351 participants
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 3 year(s) since 2025
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 OpenAlex's profile for last-listed author Wen-Teng Lee holds only 5 work(s), too few to judge a track record — left out of this score
Institution's track record 0 / 3 Shin Kong WHS Memorial Hospital: institution h-index 142 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 0 / 2 Behind a paywall — scores zero
Points 45 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 45 of the 96 points we could judge it on is 47 out of 100.
Total 47 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Drug development from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Drug development

See all studies in Drug development →